Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.

Mathias JachsCaroline SchwarzMarlene PanzerTeresa BinterStephan W AberleLukas HartlKristina DaxElmar AignerAlbert F StättermayerPetra MundaIvo GraziadeiHeidemarie HolzmannMichael TraunerHeinz ZollerMichael GschwantlerMattias Mandorfer Thomas Reiberger Peter Ferenci

Published in: Alimentary pharmacology & therapeutics (2022)

Long-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.

Keyphrases

combination therapy
machine learning
immune response
drug delivery
dendritic cells
open label
study protocol